WO2001087308B1 - Treatment of fibromyalgia and chronic fatigue syndrome - Google Patents
Treatment of fibromyalgia and chronic fatigue syndromeInfo
- Publication number
- WO2001087308B1 WO2001087308B1 PCT/US2001/010806 US0110806W WO0187308B1 WO 2001087308 B1 WO2001087308 B1 WO 2001087308B1 US 0110806 W US0110806 W US 0110806W WO 0187308 B1 WO0187308 B1 WO 0187308B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- trans
- octahydropyrimido
- pharmaceutically acceptable
- quinoline
- day
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
Abstract
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001255223A AU2001255223B2 (en) | 2000-04-21 | 2001-04-17 | Treatment of fibromyalgia and chronic fatigue syndrome |
KR1020027014073A KR20020089510A (en) | 2000-04-21 | 2001-04-17 | Treatment of Fibromyalgia and Chronic Fatigue Syndrome |
EP01928355A EP1280530A1 (en) | 2000-04-21 | 2001-04-17 | Treatment of fibromyalgia and chronic fatigue syndrome |
US10/258,203 US20030212085A1 (en) | 2001-04-17 | 2001-04-17 | Treatment of fibromyalgia and chronic fatigue syndrome |
MXPA02010410A MXPA02010410A (en) | 2000-04-21 | 2001-04-17 | Treatment of fibromyalgia and chronic fatigue syndrome. |
BR0110188-9A BR0110188A (en) | 2000-04-21 | 2001-04-17 | Selected compounds for the treatment of fibromyalgia and chronic fatigue syndromes |
JP2001583776A JP2004502651A (en) | 2000-04-21 | 2001-04-17 | Treatment of fibromyalgia and chronic fatigue syndrome |
NZ522115A NZ522115A (en) | 2000-04-21 | 2001-04-17 | Selected compounds for the treatment of fibromyalgia and chronic fatigue syndrome |
CA002404704A CA2404704A1 (en) | 2000-04-21 | 2001-04-17 | Treatment of fibromyalgia and chronic fatigue syndrome |
AU5522301A AU5522301A (en) | 2000-04-21 | 2001-04-17 | Treatment of fibromyalgia and chronic fatigue syndrome |
PCT/US2001/016522 WO2002083141A1 (en) | 2001-04-17 | 2001-07-11 | Treatment of fibromyalgia and chronic fatigue syndrome |
HK03106406.2A HK1054190A1 (en) | 2000-04-21 | 2003-09-09 | Treatment of fibromyalgia and chronic fatigue syndrome |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19896000P | 2000-04-21 | 2000-04-21 | |
US60/198,960 | 2000-04-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001087308A1 WO2001087308A1 (en) | 2001-11-22 |
WO2001087308B1 true WO2001087308B1 (en) | 2002-05-16 |
Family
ID=22735613
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/010806 WO2001087308A1 (en) | 2000-04-21 | 2001-04-17 | Treatment of fibromyalgia and chronic fatigue syndrome |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1280530A1 (en) |
JP (1) | JP2004502651A (en) |
KR (1) | KR20020089510A (en) |
CN (1) | CN1418099A (en) |
AU (2) | AU5522301A (en) |
BR (1) | BR0110188A (en) |
CA (1) | CA2404704A1 (en) |
HK (1) | HK1054190A1 (en) |
MX (1) | MXPA02010410A (en) |
NZ (1) | NZ522115A (en) |
WO (1) | WO2001087308A1 (en) |
ZA (1) | ZA200208272B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277875B1 (en) * | 2000-07-17 | 2001-08-21 | Andrew J. Holman | Use of dopamine D2/D3 receptor agonists to treat fibromyalgia |
US20100035886A1 (en) | 2007-06-21 | 2010-02-11 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
US8741918B2 (en) * | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
EP4009973A4 (en) * | 2019-08-07 | 2023-08-23 | Aclipse One, Inc. | Pharmaceutical compositions of (6as)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5073555A (en) * | 1988-04-04 | 1991-12-17 | George D. McAdory | Medicaments intended for combined use in the improvement of lymphocyte function to lower cholesterol levels |
US5696128A (en) * | 1994-07-07 | 1997-12-09 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method of regulating immune function |
IT1304904B1 (en) * | 1998-09-11 | 2001-04-05 | Eisai Co Ltd | ANTICOLINESTERASIC DERIVATIVES FOR THE TREATMENT OF FUNCTIONAL AND / OR ORGANIC SYNDROME |
ES2246485T3 (en) * | 1999-07-01 | 2006-02-16 | PHARMACIA & UPJOHN COMPANY LLC | (S, S) -REBOXETINE TO TREAT INCONTINENCE. |
DE19938823A1 (en) * | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Treatment of restless leg syndrome symptoms, using synergistic combination of alpha-2 agonist, preferably clonidine, and another neuro-psychic drug, e.g. pramipexol |
DK1274430T3 (en) * | 2000-04-21 | 2006-02-13 | Pharmacia & Upjohn Co Llc | Cabergoline for the treatment of fibromyalgia and chronic fatigue syndrome |
US6277875B1 (en) * | 2000-07-17 | 2001-08-21 | Andrew J. Holman | Use of dopamine D2/D3 receptor agonists to treat fibromyalgia |
-
2001
- 2001-04-17 JP JP2001583776A patent/JP2004502651A/en active Pending
- 2001-04-17 BR BR0110188-9A patent/BR0110188A/en not_active IP Right Cessation
- 2001-04-17 WO PCT/US2001/010806 patent/WO2001087308A1/en not_active Application Discontinuation
- 2001-04-17 AU AU5522301A patent/AU5522301A/en active Pending
- 2001-04-17 EP EP01928355A patent/EP1280530A1/en not_active Withdrawn
- 2001-04-17 CA CA002404704A patent/CA2404704A1/en not_active Abandoned
- 2001-04-17 NZ NZ522115A patent/NZ522115A/en unknown
- 2001-04-17 AU AU2001255223A patent/AU2001255223B2/en not_active Ceased
- 2001-04-17 KR KR1020027014073A patent/KR20020089510A/en not_active Application Discontinuation
- 2001-04-17 CN CN01806848A patent/CN1418099A/en active Pending
- 2001-04-17 MX MXPA02010410A patent/MXPA02010410A/en unknown
-
2002
- 2002-10-14 ZA ZA200208272A patent/ZA200208272B/en unknown
-
2003
- 2003-09-09 HK HK03106406.2A patent/HK1054190A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20020089510A (en) | 2002-11-29 |
AU5522301A (en) | 2001-11-26 |
AU2001255223B2 (en) | 2004-10-21 |
WO2001087308A1 (en) | 2001-11-22 |
BR0110188A (en) | 2003-03-05 |
MXPA02010410A (en) | 2003-04-25 |
ZA200208272B (en) | 2004-01-26 |
NZ522115A (en) | 2004-07-30 |
HK1054190A1 (en) | 2003-11-21 |
CA2404704A1 (en) | 2001-11-22 |
CN1418099A (en) | 2003-05-14 |
JP2004502651A (en) | 2004-01-29 |
EP1280530A1 (en) | 2003-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009533356A5 (en) | ||
US6281207B1 (en) | Treatment of movement disorders by administration of mirtazapine | |
HUP0401849A2 (en) | Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors | |
KR970704435A (en) | Use of Heterocyclic Compounds as Dopamine-D Ligands (Use of Heterocyclic Compounds as Dopamine-D Ligands) | |
MY132565A (en) | Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) | |
AU2878689A (en) | Locally administrable 2-amino-3-benzoyl phenylacetic acid derivatives as therapeutic compositions for inflammatory disease | |
MY132789A (en) | Diarylcycloalkyl derivatives, process for their preparation and their use as pharmaceuticals | |
JP2003520195A5 (en) | ||
JP2009513713A5 (en) | ||
JP7182605B2 (en) | Compositions comprising a lyn kinase activator and a TRPM8 agonist and their use in the manufacture of medicaments | |
JP2012513390A5 (en) | ||
RU2004139041A (en) | APPLICATION OF HETEROARENCARBOXAMIDES AS DOPAMIN-D3 LIGANDS FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | |
WO2001087308B1 (en) | Treatment of fibromyalgia and chronic fatigue syndrome | |
CA2575512A1 (en) | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors | |
UA81640C2 (en) | Antimycobacterial compounds, process for the preparation thererof, pharmaceutical composition based thereon | |
AU690661B2 (en) | New use of quinoline-3-carboxamide compounds | |
AU679633B2 (en) | New use of quinoline-3-carboxamide compounds | |
JP2005513036A5 (en) | ||
CZ111095A3 (en) | Derivatives of 3,4-dihydro-2(1h)-quinolone and pharmaceutical composition based thereon | |
JP2002522462A5 (en) | ||
CA2443235A1 (en) | Pharmaceutical compositions comprising ascomycin | |
US5476858A (en) | Use of carbostyril to increase somatostatin or for inhibiting decrease of somatostatin to treat diseases related thereto | |
CA2452920A1 (en) | Benzo [g] quinoline derivatives for treating glaucoma and myopia | |
EP0641569A1 (en) | Antipruritic | |
PT1082116E (en) | USE OF 4-PIPERIDINOMETHANOL DERIVATIVES IN THE TREATMENT OF DISORDERS OF NEURODESVOLVEMENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018068480 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2404704 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002/08272 Country of ref document: ZA Ref document number: 200208272 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10258203 Country of ref document: US Ref document number: 2001255223 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027014073 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2001 583776 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 522115 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/010410 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/2002/01491/MU Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001928355 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027014073 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001928355 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 522115 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 522115 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001255223 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001928355 Country of ref document: EP |